Li Xin (Clarithromycin) is applied across domains where additional symptomatic support is needed for a variety of bacterial infections. It is commonly used to address conditions where symptoms may intensify temporarily, contributing to easing the overall symptom load.

The medication plays a role in managing conditions characterized by periods of heightened symptoms affecting the respiratory tract, such as pneumonia, bronchitis, and sinusitis. It also addresses infections of the skin and soft tissues, and is a key component in combination therapy to address the bacterial cause of peptic ulcer disease (H. pylori).

“It is commonly used as a relevant option when alternative symptomatic assistance is needed, supporting the patient during episodes of heightened discomfort.”

In these contexts, it helps address symptom clusters that may become intense or disruptive, including fever, cough, sore throat, and localized redness and swelling. This application is relevant when supportive symptom management is appropriate, contributing to easing the overall symptom load and improved comfort.

Focus Fact: Relief for Acute Respiratory Discomfort

Regulatory References

1. NIH MedlinePlus overview of Clarithromycin

Li Xin (Clarithromycin) is strictly governed by regulatory eligibility rules defining who may use the medicine and under what conditions. Adults and children six months of age and older are generally eligible, though safety is not established in infants younger than six months. For children under 12, the tablet formulation is not recommended.

Contraindications

Use is prohibited (contraindicated) in patients with a known macrolide allergy or a history of cholestatic jaundice associated with prior macrolide use. It is also prohibited for individuals with pre-existing QT prolongation or ventricular cardiac arrhythmias, including those with uncorrected hypokalaemia.

Eligibility Restrictions

A critical restriction is concurrent use with certain medications, including Lovastatin, Simvastatin, Ergot Alkaloids, Cisapride, and Pimozide. Patients with severe renal impairment (creatinine clearance less than 30 mL/min) remain eligible but must have their dosage reduced by one-half. Use is not recommended during pregnancy unless no suitable alternative is available, and discontinuation of breastfeeding is necessary during treatment.

Interactions with other medicines and products

Li Xin (Clarithromycin) is a strong inhibitor of the CYP3A4 enzyme and the P-glycoprotein (P-gp) transporter, which form the primary basis for its officially documented interactions. This mechanism significantly alters the plasma exposure of many co-administered medicinal products.

Formal Contraindications

Co-administration with certain medicines is strictly contraindicated by regulatory authorities due to high risk of severe adverse events:

• HMG-CoA Reductase Inhibitors: Co-use with lovastatin or simvastatin is prohibited due to the increased risk of myopathy, including rhabdomyolysis.
• Ergot Alkaloids: Co-use with ergotamine or dihydroergotamine is prohibited due to the risk of acute ergot toxicity (vasospasm/ischemia).
• Proarrhythmic Agents: Co-use with drugs such as cisapride, pimozide, astemizole, or terfenadine is prohibited due to the risk of QT prolongation and serious cardiac arrhythmias, including Torsades de Pointes.

Population and Administration Constraints

Specific regulatory constraints exist for certain populations and products:

• Colchicine co-administration is contraindicated in patients with co-existing renal or hepatic impairment.
• Administration of Li Xin and Zidovudine must be separated by at least 2 hours to avoid decreased exposure of Zidovudine.
• CYP3A4 inducers (e.g., rifampicin, phenytoin, St John’s wort) may reduce Clarithromycin plasma levels, potentially leading to subtherapeutic exposure. The extended-release formulation should be taken with food.

Inhibition of Bacterial Protein Synthesis

Li Xin works by engaging with the 50S ribosomal subunit, a core molecular factory within the bacterial cell responsible for making proteins. The drug binds specifically to the 23S ribosomal RNA (rRNA), physically obstructing the exit tunnel through which nascent peptide chains must pass. This immediate blockade arrests the process of protein translation, inhibiting the synthesis of proteins essential for bacterial proliferation. This cascade results in a bacteriostatic functional state within the cell, characterized by the inhibition of replication.

---

Mechanistic Limitations by Bacterial Resistance

The drug's mechanism is biologically constrained by the development of bacterial resistance. Resistance occurs primarily when bacteria acquire the ability to chemically modify the drug's target site through methylation of the 23S rRNA, which prevents the drug from binding effectively. Alternatively, bacteria can utilize efflux pumps that actively transport the Clarithromycin molecule out of the cell before it can reach the 50S subunit. These constraints prevent the drug's inhibitory mechanism from initiating, allowing bacterial protein synthesis and proliferation to proceed unimpaired by the molecule.

Administration Overview

Li Xin is typically administered in a clinical or home setting depending on the specific requirements of the treatment plan. Proper use involves consistent timing and adherence to the method prescribed by a healthcare professional.

Methods of Use

• Oral Administration: When provided in oral form, the medication is usually taken with water. It may be taken with or without food, though consistency in how it is consumed is important for maintaining stable levels in the body.
• Preparation: If the medication requires preparation, such as dissolving or mixing, it should be handled with clean hands and used immediately after preparation to ensure integrity.

Routine Management

Maintaining a regular schedule is a key component of using Li Xin. Many patients find it helpful to use tools such as daily planners or digital reminders to ensure the medication is integrated into their daily routine at the same time each day.

Handling and Storage

• Storage Environment: The medication should be kept in its original packaging to protect it from environmental factors.
• Temperature: Store the product in a cool, dry place away from direct sunlight and moisture.
• Accessibility: Keep the medication in a secure location that is not easily accessible to unauthorized individuals or pets.

Research Evidence / Overview of Studies for Li Xin (Clarithromycin)

---

Evidence Supporting Use in Community-Acquired Respiratory Infections

The primary research for Li Xin has focused on evaluating its role in bacterial infections affecting the lungs and airways, such as pneumonia and bronchitis. These investigations typically rely on Randomized Controlled Trials (RCTs), where studies examined Li Xin against comparator medicines, such as other antibiotics. Research explored Li Xin’s role by monitoring outcomes related to short-term changes in clinical status, including rates of symptom resolution at designated follow-up visits.

However, the patterns observed in the research are subject to a complex factor: bacterial resistance. Research highlights that bacterial resistance rates to Li Xin vary widely across different geographical locations, which means that generalizability of findings from studies conducted in one region may be limited to patients in another. This variability is a known research limitation.

---

Research for Helicobacter pylori Eradication Regimens

Li Xin was studied for its use as a core component of multi-drug regimens—often called triple therapy—to investigate H. pylori eradication. The main goal of these studies is to measure the Eradication Rate, confirmed by testing conducted several weeks after treatment. Reports show that the rates of successful eradication associated with Li Xin in combination regimens have changed over time. Findings consistently describe that the prevalence of clarithromycin resistance in H. pylori strains locally was associated with variability in eradication rates. Other comparative research was also described in limited settings.

---

Research Gaps and Remaining Uncertainty

The majority of evidence is derived from short-term RCTs. The typical observation periods for research are usually limited to the treatment duration plus a short follow-up period. There is limited information for long-term outcomes regarding the durability of the initial response across many common infections. Furthermore, subgroup findings are uncertain or less numerous for older adults with multiple comorbidities. The evidence quality varied across studies, and further exploration is ongoing to address these uncertainties.

Key Studies & References

1. CLArithromycin Versus AZIthromycin in the Treatment of Mycobacterium Avium Complex (MAC) Lung Infections (Trial Summary)
2. Disseminated Mycobacterium avium Complex: Adult and Adolescent OIs (NIH Clinical Info HIV Guidelines)
3. The prevalence of clarithromycin-resistant Helicobacter pylori isolates: a systematic review and meta-analysis

Common questions about Li Xin (FAQ)

Q: How quickly does Li Xin start working?

According to the official product information, the onset of therapeutic effect for Li Xin is typically observed within one week for most patients. Patients are generally advised to continue taking the medication as prescribed by their healthcare provider. Studies and official information indicate that the full benefit may take longer than one week to develop.

Q: Can Li Xin be used during pregnancy?

Regulatory documents state that the use of Li Xin is not recommended during pregnancy. This is due to a lack of sufficient safety data regarding its effects on pregnant women and the potential for fetal risk. Patients should consult their healthcare provider regarding pregnancy planning or if they become pregnant while using this medication.

Q: Is Li Xin available as an oral tablet or an injection?

Official product information indicates that Li Xin is available in an oral tablet formulation. This means the medicine is taken by mouth. Official labeling lists only the oral tablet formulation.

Q: Do I need to avoid any specific foods while taking this medicine?

According to the official product information, there are no specific dietary restrictions listed for Li Xin. The medicine can be taken with or without food, as this does not impact its effectiveness. Patients should always follow the specific treatment regimen outlined by their prescribing healthcare provider.

Li Xin, which contains Clarithromycin, must be stored and disposed of according to strict regulatory guidelines to maintain its stability.

Storage Conditions

Tablets must be stored at controlled room temperature, typically 20 C to 25 C. The product must be kept in its original, tightly closed container and should be protected from light, heat, and moisture. The prepared liquid suspension is stable for 14 days and must not be frozen. All forms of the medicine must be stored out of the reach and sight of children.

Disposal

Disposal must adhere to local environmental and pharmaceutical waste regulations. Unused or expired medicine should not be disposed of in household waste or wastewater. The preferred method is to use a community drug take-back program or to mix the product with an undesirable substance (e.g., used coffee grounds) before discarding securely in the trash.